Bridgeway Capital Management’s Pyxis Oncology PYXS Stock Holding History
Bought
Maintained
Sold
Other funds holding PYXS
Bridgeway Capital Management's PYXS Position: Q3 2026 in Review
Bridgeway Capital Management increased its Pyxis Oncology (PYXS) stake by 33% in Q3 2026, buying an estimated $80.4K and bringing the position to 107,824 shares worth $251K. The position accounts for ﹤0.01% of the portfolio, ranked #964.
Bridgeway Capital Management first reported a position in PYXS in Q2 2022 and has held it in 18 quarters since. The position peaked at $986K in Q1 2024. 101 funds tracked by Wall St. Rank hold PYXS as of Q3 2026.
- Bridgeway Capital Management held 107,824 shares of Pyxis Oncology worth $251K as of Q3 2026.
- Bridgeway Capital Management bought 26,564 Pyxis Oncology shares in Q3 2026, an estimated $80.4K.
- Pyxis Oncology made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q3 2026, its #964 holding.
- Bridgeway Capital Management first reported a position in Pyxis Oncology in Q2 2022 and has held it in 18 quarters since.
- Bridgeway Capital Management's Pyxis Oncology position peaked at $986K in Q1 2024.
- 101 funds tracked by Wall St. Rank held Pyxis Oncology as of Q3 2026.
Based on Bridgeway Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.